TNT to Increase the Clinical Complete Response Rate for Distal LARC

Inclusion Criteria: * Rectal adenocarcinoma * cT3-4aNany or cTanyN+ * Location ≤5 cm from the anal verge * No distant metastasis * No gastrointestinal obstruction or relieved obstruction * No previous surgery of the rectum, no previous chemotherapy, no previous pelvic radiation, no previous biotherapy * ECOG 0-1 * Expected survival length ≥ 2 years * Age 18-70 * Sufficient bone marrow, kidney and liver function * Effective contraception during the study * Patient and doctor have signed informed consent Exclusion Criteria: * Distant metastasis * Chronic intestinal inflammation and/or bowel obstruction * Contra indication for chemotherapy and/or radiotherapy * Previous pelvic radiotherapy or chemotherapy * Severe renal, hepatic insufficiency (serum creatinine\<30ml/min) * Peripheral neuropathy \> grade 1 * Pregnant or breast-feeding woman * Certain or suspicious allergy to research drug * Cachexia, organ dysfunction * Active severe infection * Multiple primary cancers * Epileptic seizures * Malignant history within 5 years, except cervical carcinoma in situ or cutaneous basal cell carcinoma * Severe arrhythmia, cardiac dysfunction (NYHA grade III or IV ) * Uncontollable severe hypertesion * Persons deprived of liberty or under guardianship * Impossibility for compliance to follow-up